Product Name: KinSub1RRLSF
Product Number: PE-01AJJ95
Size: 200 µg      Price:99.00
      $US
Peptide Name: KinSub1RRLSF

Product Use: For assaying the phosphotransferase activity of p21-activated kinase 5; Protein-serine/threonine kinase PAK7 (UniProt ID Q9P286). The KinSub1RRLSF peptide demonstrated high phosphotransferase activity with PAK5 (PAK7), and exhibited very high specificity when assayed with over 200 other protein kinases. A listing of other kinases that show appreciable phosphotransferase activity towards this peptide are listed in Table 1.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: KinSub1RRLSF was originally identified using a microarray with peptides that were predicted as optimal substrates for 500 human protein kinases with a proprietary algorithm developed at Kinexus with our academic partners.

Peptide Sequence: GGLGRRLSFGGFGGG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1393.6 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: PAK5 (PAK7)

Scientific Background: PAK5 is one of several protein kinases that can phosphorylate KinSub1RRLSF. Human PAK5 (also known as PAK7) is a protein-serine/threonine kinase of 719 amino acid length, with a predicted molecular mass of 80745 Da. It is a member of the STE group of protein kinases in the STE20 family, and PAKB subfamily. This kinase appears to have a restricted human tissue expression with the highest levels detected in brain, spinal cord and the adrenal gland. Orthologues of PAK5 (PAK7) are highly conserved in vertebrates and insects. PAK5 has been implicated in the regulation of cell morphology, motility and transformation. PAK5 features a CDC42/Rac1 interactive binding (CRIB) motif at the N-terminus and a Ste20-like kinase domain at the C-terminus (1). Binding of GTP-bound Cdc42 or Rac1 to the autoregulatory region at the N-terminus of PAK5 releases monomers from the autoinhibited dimer, enables activation of its phosphotransferase activity. PAK5 has been linked with the development of colorectal adenocarcinomas, lung adenocarcinomas, and melanomas (metastatic).